STAT3 and hepatocellular carcinoma: In the orthotopic HCC model, we used the aforementioned miR‐125b‐5p‐loaded nanomedicine to activate the miR‐125b‐5p/STAT3 axis of hepatoma cells and reduce wnt/β‐Catenin pathway activity, which realized the expected EMT and CSC in vivo inhibition functions.